Program Status
RecruitingPhase
Phase 1Prior Immunotherapy Allowed
NoCRC-directed Trial
YesDrugs
Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, YervoyTags
MSS/ MMRpComments
Prof. Niels Halama is Principal Investigator. This is a trial “with Maraviroc”, a continuation of the the MARACON trial and of PICCASSO trial (NCT03274804). See Helpful Links.